Welcome to Chiesi
Spain
The history of Chiesi Group dates back to 6th July 1935. Italian pharmacist Giacomo Chiesi, a person with an innate vocation for his occupation, scientific concerns and a great human warmth, bought the Parmesan Pharmaceutical Laboratory. In this undersized provincial laboratory and with just two employees, he started his business adventure.
The commitment and dedication of this pharmacist, shared with his family and spread to all those people that surround him, let him start to grow soon. At the end of the 1970s the first foreign subsidiary was opened. The country chosen was Brazil. Thus, the Italian pharmaceutical company began to make its way internationally.
The legacy of this pharmaceutical entrepreneur is still alive thanks to his sons Alberto and Paolo. With them, Chiesi has become in an international group with more than 7,000 employees that operates in five continents and that it is continuous expansion.
What started as a personal dream, 90 years ago, with only two employees is today a collective reality with more than 7,000 employees around the world.
After 90 years, this pharmaceutical company with its headquarters in Parma (Italy) has become in an enterprising and innovative multinational with special focus in the respiratory, neonatology and rare diseases areas.
Chiesi Group has a firm commitment with those patients with prevalent chronic diseases, especially in the respiratory area, but also those that suffer from rare diseases with non covered necessities. Outcome of this commitment, the company constantly invests in research and development.
-
Chiesi began operating in Spain in 1995 with the acquisition of Laboratorios Wassermann. In 2003, it acquired Laboratorios Dreiman, the pharmaceutical division of Laboratorios Alcalá Farma and the Advent International Group. In 2023, it established a branch in Portugal. Nowadays, Chiesi Spain has become one of the main subsidiaries of the group in terms of billing.
In 2023, the Chiesi Group exceeded €3 billion in revenues, representing growth of 10% (+12% @CER) compared to the previous year, maintaining an EBIDTA of approximately 30% for the fourth consecutive year. The company has strengthened its performance in all regions and business areas; at constant exchange rates (@CER), the figures show growth in the Group's three therapeutic areas: AIR - respiratory diseases; RARE - rare and ultra-rare diseases; and CARE - specialized care, neonatology and consumer healthcare; and in all the regions in which it is present: United States, up 25%; Europe, up 7%; and China and international, up 22%.
Commitment to innovation continues to be key to the Chiesi Group's growth. Approximately 24% of total revenues for the year are invested in research and development (R&D) with the aim of boosting both the internal product portfolio and accelerating external collaborations.
